Compare EVER & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVER | NTLA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 986.9M |
| IPO Year | 2018 | 2016 |
| Metric | EVER | NTLA |
|---|---|---|
| Price | $27.37 | $9.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 22 |
| Target Price | ★ $33.00 | $19.83 |
| AVG Volume (30 Days) | 411.8K | ★ 4.5M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 284.14 | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $644,656,000.00 | $57,528,000.00 |
| Revenue This Year | $36.72 | $1.96 |
| Revenue Next Year | $13.44 | N/A |
| P/E Ratio | $19.28 | ★ N/A |
| Revenue Growth | ★ 57.83 | 33.52 |
| 52 Week Low | $16.63 | $5.90 |
| 52 Week High | $30.03 | $28.25 |
| Indicator | EVER | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 40.70 |
| Support Level | $27.37 | $9.15 |
| Resistance Level | $28.73 | $9.68 |
| Average True Range (ATR) | 0.98 | 0.53 |
| MACD | -0.04 | 0.40 |
| Stochastic Oscillator | 65.65 | 54.69 |
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.